The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Open accessAbstract
Pathway-specific therapy is the future of cancer management. The oncogenic phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in solid tumors; however, currently, no reliable test for PI3K pathway activation exists for human tumors. Taking advantage of the observation that loss of PTEN, the negative regulator of PI3K, results in robust activation of this pathway, we developed and validated a microarray gene expression signature for immunohistochemistry (IHC)-detectable PTEN loss in breast cancer (BC). The most significant signature gene was PTEN itself, indicating that PTEN mRNA levels are the primary determinant of PTEN protein levels in BC. Some PTEN IHC-positive BCs exhibited the signature of PTEN loss, which was associated to moderately reduced PTEN mRNA levels cooperating with specific types of PIK3CA mutations and/or amplification of HER2 . This demonstrates that the signature is more sensitive than PTEN IHC for identifying tumors with pathway activation. In independent data sets of breast, prostate, and bladder carcinoma, prediction of pathway activity by the signature correlated significantly to poor patient outcome. Stathmin, encoded by the signature gene STMN1 , was an accurate IHC marker of the signature and had prognostic significance in BC. Stathmin was also pathway-pharmacodynamic in vitro and in vivo . Thus, the signature or its components such as stathmin may be clinically useful tests for stratification of patients for anti-PI3K pathway therapy and monitoring therapeutic efficacy. This study indicates that aberrant PI3K pathway signaling is strongly associated with metastasis and poor survival across carcinoma types, highlighting the enormous potential impact on patient survival that pathway inhibition could achieve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Whitfield, M. L., Sherlock, G., Saldanha, A. J., Murray, J. I., Ball, C. A., Alexander, K. E., Matese, J. C., Perou, C. M., Hurt, M. M., Brown, P. O., et al. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.02-02-0030 · Cited by 1,527
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K., & Clarke, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063994 · Cited by 985
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J.-T., Rijn, M. V. D., Botstein, D., & Brown, P. O. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020007 · Cited by 951
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Self-citationGene expression profiling predicts clinical outcome of prostate cancer
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M., & Gerald, W. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20032 · Cited by 479
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Saal, L. H., Troein, C., Vallon-Christersson, J., Gruvberger, S., Borg, Å., & Peterson, C. (2002) · Genome Biology · doi:10.1186/gb-2002-3-8-software0003 · Cited by 462
Self-citationMicroarray Analysis and Tumor Classification
Quackenbush, J. (2006) · New England Journal of Medicine · doi:10.1056/nejmra042342 · Cited by 455
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR
Ramaswamy, S., Nakamura, N., Sansal, I., Bergeron, L., & Sellers, W. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00086-7 · Cited by 428
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Self-citationChromogenic in Situ Hybridization
Tanner, M., Gancberg, D., Di Leo, A., Larsimont, D., Rouas, G., Piccart, M. J., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64785-2 · Cited by 383
Self-citationPerren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378
Bladder Cancer Outcome and Subtype Classification by Gene Expression
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., DeVries, S., Koppie, T., Pejavar, S., Carroll, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2409 · Cited by 337
Tang, J.-M., He, Q.-Y., Guo, R.-X., & Chang, X.-J. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.10.003 · Cited by 332
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., Mansukhani, M., Murty, V. V. V. S., Gaciong, Z., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328
Self-citationLoss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer
Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 294
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Alli, E., Bash-Babula, J., Yang, J., & Hait, W. N. (2002) · PubMed · Cited by 187
Microarray expression profiling in melanoma reveals a BRAF mutation signature
Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S.-J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207563 · Cited by 183
Self-citationPanigrahi, A., Pinder, S., Chan, S., Paish, E., Robertson, J., & Ellis, I. (2004) · The Journal of Pathology · doi:10.1002/path.1611 · Cited by 164
Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours
Curmi, P. A., Noguès, C., Lachkar, S., Calmels, N., Gonthier, M., Sobel, A., Lidereau, R., & Bièche, I. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0891 · Cited by 133
Brattsand, G. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1264 · Cited by 115
Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer
Shah, A., Swain, W. A., Richardson, D. L., Edwards, J. G., Stewart, D. J., Richardson, C. M., Swinson, D., Patel, D., Jones, J. L., & O'Byrne, K. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1385 · Cited by 93
Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN.
Matsushima-Nishiu, M., Unoki, M., Ono, K., Tsunoda, T., Minaguchi, T., Kuramoto, H., Nishida, M., Satoh, T., Tanaka, T., & Nakamura, Y. (2001) · PubMed · Cited by 90
Gerner, C., Vejda, S., Gelbmann, D., Bayer, E., Gotzmann, J., Schulte‐Hermann, R., & Mikulits, W. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200026-mcp200 · Cited by 89
Stolarov, J. P., Chang, K., Reiner, A. H., Rodgers, L., Hannon, G. J., Wigler, M. H., & Mittal, V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221450598 · Cited by 57
p27Kip1 and stathmin share the stage for the first time
Iancu‐Rubin, C., & Atweh, G. F. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.05.008 · Cited by 51
Janzen, V., & Scadden, D. T. (2006) · Nature · doi:10.1038/441418b · Cited by 28
Cited by
What is principal component analysis?
Ringnér, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0308-303 · Cited by 2,407
Self-citationCarver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Self-citationAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Metadata
- Authors
- Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., Isola, J., Bendahl, P.-O., Rosen, N., Hibshoosh, H., Ringnér, M., Borg, Å., & Parsons, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-05
- Volume
- 104
- Issue
- 18
- Pages
- 7564-7569
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2128613144
- Cited by
- 520
- References
- 40
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.